Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study

Registry ID

EUCTR2014-000496-64

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Dr. Daniel Podzamczer Palter. Hospital Univesitari de Bellvitge. Unidad de VIH.

Start date

2014-04-23

Completion date

2016-04-01

Last update

2026-08-16

Conditions

• HIV-1 infection

Summary

To determine HIV-1 RNA in CSF in HIV-1 infected subjects receiving treatment with Atazanavir 300 mg boosted with Ritonavir 100 mg plus lamivudine 300 mg

Locations

• , , Spain

Related clinical trials

• Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People with HIV-1

View on source registry